Edgar Filing: DEXCOM INC - Form 4

DEXCOM INC Form 4 August 26, 2016 FORM 4 Number: 0MB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).											
(Print or Type F	Responses)										
Balo Andrew K S				2. Issuer Name and Ticker or Trading Symbol DEXCOM INC [DXCM]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)	3. Date of	f Earliest Tı	ansaction			(Cnec	k all applicable	;)	
(M				(Month/Day/Year) 08/24/2016				Director10% Owner XOfficer (give titleOther (specify below)below) EVP, Clinical and Regulatory			
				Amendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SAN DIEGO	D, CA 92121							Form filed by M Person	Iore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-E	erivative	Secur	ities Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	 Execution any 		Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	(A) or	d of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common	001041001			Code V	Amount	(D)	Price		D		
Stock	08/24/2016			М	5,000	А	\$ 3.19	134,979	D		
Common Stock	08/24/2016			S	5,000 (1)	D	\$ 91.72	129,979 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: DEXCOM INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Share
Non-Qualified Stock Option (right to buy)	\$ 3.19	08/24/2016		М	5,000	12/11/2009	12/11/2018	Common Stock	5,0

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
Balo Andrew K 6340 SEQUENCE DRIVE SAN DIEGO, CA 92121			EVP, Clinical and Regulatory				
Signatures							
By: Kevin Sun For: Andrew K. Balo		08/26/201					
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

Included in this number are 86,333 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 31,666 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 16,667 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

Remarks:

CONFIRMING STATEMENT: This Statement confirms that the undersigned Andrew K. Balo, has authorized and designated

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.